These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10767389)

  • 21. p53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer.
    Veloso M; Wrba F; Kaserer K; Heinze G; Magalhães A; Herbst F; Teleky B
    Virchows Arch; 2000 Sep; 437(3):241-7. PubMed ID: 11037343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival.
    Barbareschi M; Caffo O; Doglioni C; Fina P; Marchetti A; Buttitta F; Leek R; Morelli L; Leonardi E; Bevilacqua G; Dalla Palma P; Harris AL
    Br J Cancer; 1996 Jul; 74(2):208-15. PubMed ID: 8688323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression.
    Kouvidou C; Stefanaki K; Dai Y; Tzardi M; Koutsoubi K; Darivianaki K; Karidi E; Rontogianni D; Zois E; Kakolyris S; Georgoulias V; Delides G; Kanavaros P
    Anticancer Res; 1997; 17(4A):2615-9. PubMed ID: 9252690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
    Wolf HK; Stöber C; Hohenfellner R; Leissner J
    Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas.
    Stefanaki K; Rontogianni D; Kouvidou CH; Bolioti S; Delides G; Pantelidaki A; Sotsiou F; Kanavaros P
    Histopathology; 1997 Jun; 30(6):549-55. PubMed ID: 9205859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
    Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH
    Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years.
    Domagala W; Welcker M; Chosia M; Karbowniczek M; Harezga B; Bartkova J; Bartek J; Osborn M
    Virchows Arch; 2001 Aug; 439(2):132-40. PubMed ID: 11561753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
    Jahnson S; Karlsson MG
    Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index.
    Ng IO; Lam KY; Ng M; Regezi JA
    Oral Oncol; 1999 Jan; 35(1):63-9. PubMed ID: 10211312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
    Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
    J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of MDM2 protein and low rate of p21(WAF1/CIP1) expression in SCID mice Epstein Barr virus-induced lymphoproliferation.
    El Mansouri S; Martin A; Mercadier A; Capoulade C; Maréchal V; Wiels J; Feuillard J; Raphaël M
    J Histochem Cytochem; 1999 Oct; 47(10):1315-22. PubMed ID: 10490460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.
    Jiang M; Shao ZM; Wu J; Lu JS; Yu LM; Yuan JD; Han QX; Shen ZZ; Fontana JA
    Int J Cancer; 1997 Oct; 74(5):529-34. PubMed ID: 9355976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
    Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
    Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
    Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
    Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
    Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
    J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.
    Sanchez E; Chacon I; Plaza MM; Muñoz E; Cruz MA; Martinez B; Lopez L; Martinez-Montero JC; Orradre JL; Saez AI; Garcia JF; Piris MA
    J Clin Oncol; 1998 May; 16(5):1931-9. PubMed ID: 9586912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.